Logo image of IONS

IONIS PHARMACEUTICALS INC (IONS) Stock Fundamental Analysis

NASDAQ:IONS - Nasdaq - US4622221004 - Common Stock - Currency: USD

31.64  -0.49 (-1.53%)

After market: 31.64 0 (0%)

Fundamental Rating

3

IONS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. While IONS seems to be doing ok healthwise, there are quite some concerns on its profitability. IONS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

IONS had negative earnings in the past year.
In the past year IONS has reported a negative cash flow from operations.
IONS had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: IONS reported negative operating cash flow in multiple years.
IONS Yearly Net Income VS EBIT VS OCF VS FCFIONS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M -400M 600M

1.2 Ratios

The Return On Assets of IONS (-11.65%) is better than 86.55% of its industry peers.
IONS has a better Return On Equity (-54.16%) than 63.54% of its industry peers.
Industry RankSector Rank
ROA -11.65%
ROE -54.16%
ROIC N/A
ROA(3y)-8%
ROA(5y)-6.8%
ROE(3y)-48.5%
ROE(5y)-37.28%
ROIC(3y)N/A
ROIC(5y)N/A
IONS Yearly ROA, ROE, ROICIONS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 -40 -60 -80

1.3 Margins

Looking at the Gross Margin, with a value of 98.70%, IONS belongs to the top of the industry, outperforming 98.05% of the companies in the same industry.
In the last couple of years the Gross Margin of IONS has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for IONS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 98.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.16%
GM growth 5Y-0.17%
IONS Yearly Profit, Operating, Gross MarginsIONS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50

More info and screens

4

2. Health

2.1 Basic Checks

IONS does not have a ROIC to compare to the WACC, probably because it is not profitable.
IONS has more shares outstanding than it did 1 year ago.
IONS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for IONS has been reduced compared to a year ago.
IONS Yearly Shares OutstandingIONS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M
IONS Yearly Total Debt VS Total AssetsIONS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 1B 2B 3B

2.2 Solvency

Based on the Altman-Z score of 1.09, we must say that IONS is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 1.09, IONS is doing good in the industry, outperforming 67.26% of the companies in the same industry.
IONS has a Debt/Equity ratio of 1.86. This is a high value indicating a heavy dependency on external financing.
IONS's Debt to Equity ratio of 1.86 is on the low side compared to the rest of the industry. IONS is outperformed by 82.12% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.86
Debt/FCF N/A
Altman-Z 1.09
ROIC/WACCN/A
WACC9.65%
IONS Yearly LT Debt VS Equity VS FCFIONS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500M 1B

2.3 Liquidity

A Current Ratio of 8.91 indicates that IONS has no problem at all paying its short term obligations.
With a decent Current ratio value of 8.91, IONS is doing good in the industry, outperforming 75.93% of the companies in the same industry.
IONS has a Quick Ratio of 8.82. This indicates that IONS is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 8.82, IONS is doing good in the industry, outperforming 75.93% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.91
Quick Ratio 8.82
IONS Yearly Current Assets VS Current LiabilitesIONS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B 2.5B

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 36.79% over the past year.
The Revenue has grown by 30.58% in the past year. This is a very strong growth!
IONS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.60% yearly.
EPS 1Y (TTM)36.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.77%
Revenue 1Y (TTM)30.58%
Revenue growth 3Y2.6%
Revenue growth 5Y5.6%
Sales Q2Q%-6.94%

3.2 Future

IONS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.64% yearly.
The Revenue is expected to grow by 22.59% on average over the next years. This is a very strong growth
EPS Next Y-38.64%
EPS Next 2Y-22.82%
EPS Next 3Y-3.36%
EPS Next 5Y20.64%
Revenue Next Year-2.73%
Revenue Next 2Y3.34%
Revenue Next 3Y13.27%
Revenue Next 5Y22.59%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IONS Yearly Revenue VS EstimatesIONS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
IONS Yearly EPS VS EstimatesIONS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IONS. In the last year negative earnings were reported.
Also next year IONS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IONS Price Earnings VS Forward Price EarningsIONS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IONS Per share dataIONS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

IONS's earnings are expected to decrease with -3.36% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-22.82%
EPS Next 3Y-3.36%

More info and screens

0

5. Dividend

5.1 Amount

IONS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IONIS PHARMACEUTICALS INC

NASDAQ:IONS (2/4/2025, 8:00:02 PM)

After market: 31.64 0 (0%)

31.64

-0.49 (-1.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/bmo
Earnings (Next)02-19 2025-02-19/amc
Inst Owners94.22%
Inst Owner Change-0.08%
Ins Owners0.73%
Ins Owner Change8.92%
Market Cap5.00B
Analysts81.29
Price Target61.78 (95.26%)
Short Float %6.63%
Short Ratio6.34
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.8%
Min EPS beat(2)19.5%
Max EPS beat(2)52.1%
EPS beat(4)4
Avg EPS beat(4)43.28%
Min EPS beat(4)8.61%
Max EPS beat(4)92.92%
EPS beat(8)7
Avg EPS beat(8)21.61%
EPS beat(12)10
Avg EPS beat(12)53.41%
EPS beat(16)12
Avg EPS beat(16)42.04%
Revenue beat(2)2
Avg Revenue beat(2)24.06%
Min Revenue beat(2)0.96%
Max Revenue beat(2)47.15%
Revenue beat(4)3
Avg Revenue beat(4)29.07%
Min Revenue beat(4)-14.17%
Max Revenue beat(4)82.33%
Revenue beat(8)6
Avg Revenue beat(8)18.67%
Revenue beat(12)9
Avg Revenue beat(12)19.1%
Revenue beat(16)10
Avg Revenue beat(16)11.93%
PT rev (1m)-0.7%
PT rev (3m)-1.87%
EPS NQ rev (1m)-5.5%
EPS NQ rev (3m)-15.5%
EPS NY rev (1m)-1.67%
EPS NY rev (3m)6.02%
Revenue NQ rev (1m)-3.5%
Revenue NQ rev (3m)-20.96%
Revenue NY rev (1m)-0.59%
Revenue NY rev (3m)-0.86%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.22
P/FCF N/A
P/OCF N/A
P/B 7.54
P/tB 7.54
EV/EBITDA N/A
EPS(TTM)-2.44
EYN/A
EPS(NY)-3.86
Fwd EYN/A
FCF(TTM)-2.35
FCFYN/A
OCF(TTM)-2.23
OCFYN/A
SpS5.09
BVpS4.2
TBVpS4.2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.65%
ROE -54.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 98.7%
FCFM N/A
ROA(3y)-8%
ROA(5y)-6.8%
ROE(3y)-48.5%
ROE(5y)-37.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.16%
GM growth 5Y-0.17%
F-Score6
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity 1.86
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 151.88%
Cap/Sales 2.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.91
Quick Ratio 8.82
Altman-Z 1.09
F-Score6
WACC9.65%
ROIC/WACCN/A
Cap/Depr(3y)115.43%
Cap/Depr(5y)157.47%
Cap/Sales(3y)2.39%
Cap/Sales(5y)2.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.77%
EPS Next Y-38.64%
EPS Next 2Y-22.82%
EPS Next 3Y-3.36%
EPS Next 5Y20.64%
Revenue 1Y (TTM)30.58%
Revenue growth 3Y2.6%
Revenue growth 5Y5.6%
Sales Q2Q%-6.94%
Revenue Next Year-2.73%
Revenue Next 2Y3.34%
Revenue Next 3Y13.27%
Revenue Next 5Y22.59%
EBIT growth 1Y33.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.29%
EBIT Next 3Y5.01%
EBIT Next 5YN/A
FCF growth 1Y-421.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-371.75%
OCF growth 3YN/A
OCF growth 5YN/A